Drug Approval | December 04, 2025
FDA expands nod of Eli Lilly’s Jaypirca for earlier CLL/SLL treatment
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
The PCR-based test, delivered via Roche’s cobas liat system, allows results to be obtained during a patient consultation in GP practices and Emergency Rooms
Here's a development that aims to keep your blood pressure in check. Literally!
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
Angelini Ventures has already invested €125 million in 22 startups
LYMPHIR addresses a clear clinical need in a disease with limited treatment options
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
Here's a new ray of hope for new hope for patients suffering from Meniere’s disease (MD) and sensorineural hearing loss
FDA's withholding of the PRV was contrary to law because no drug product containing phenobarbital sodium was 'previously approved'
Suffering from acute migraine? You may soon bid adieu to the debilitating headache
Subscribe To Our Newsletter & Stay Updated
